Evaluate GERN stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in GERN? | Glauxie AI

Q: What are the risks of investing in GERN?

Geron Corporation (GERN) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Harout Semerjian. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a... Employees: 64,000.

Q: How much debt does GERN have?

Review GERN total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is GERN a good long-term investment?

Evaluate GERN as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in GERN?

🦉

Geron Corporation (GERN)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOHarout Semerjian

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation...

Key Executives

Name	Title
Ahmed ElNawawi	Executive Vice President & Chief Commercial Officer
Aron Feingold	Vice President of Investor Relations & Corporate Communications
Bryan Ridgell	Senior Vice President of Portfolio & Project Management and Chief of Staff
Dawn Schottlandt	Senior Vice President of Investor Relations & Corporate Affairs
Harout Semerjian	Chief Executive Officer, President & Director
Joseph Emile Eid	Executive Vice President of Research & Development and Chief Medical Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

GERN Profile Financials

Is GERN stock safe? How much debt does GERN have? Is GERN a good long-term investment?